Exopharm released an update today from Ian Dixon the CEO, providing detail on where the company is focusing its commercialisation efforts. The company is firstly aiming to do multiple deals licensing its LEAP technology platform. This will enable industry players to produce purified exosomes at the scale needed for this emerging field of new medicines. Secondly Exopharm is focused on partnering with pharmaceutical companies to deliver both existing and new drugs with more precision, with the intention of improving efficacy using its EVPS and LOAD technology platforms. Finally, the company is also developing entirely new exosome medicines which it can invest in and then look to partner with pharmaceutical companies. Examples include Fortrexo which targets viruses like COVID-19 and Cognevo which focuses on neurological diseases.